BACKGROUND: RAD51D and RAD54L are involved in homologous recombination, and rare mutations in RAD51D were recently found in breast-ovarian cancer families. This study investigated RAD51D and RAD54L for mutations in breast and ovarian cancer patients in the Finnish population. METHODS: The study sequenced the RAD51D and RAD54L genes in 95 breast and/or ovarian cancer families and genotyped the identified mutation in an additional 2200 breast and 553 ovarian cancer patients and 2102 population controls. To investigate the role of the mutation in other common cancers, 1094 prostate and 980 colorectal cancer patients were genotyped. RESULTS: In the screening of RAD51D, one deleterious founder mutation c.576+1G>A was identified in two breast-ovarian cancer families. No mutations were found in RAD54L. Altogether, the c.576+1G>A mutation was detected in 5/707 patients with a personal or family history of ovarian cancer (OR 9.16, 95% CI 1.07 to 78.56; p=0.024), with the highest frequency among breast-ovarian cancer families (3/105 vs 1/1287 controls, OR 37.82, 95% CI 3.90 to 366.91; p=0.0016), but no elevated frequency among breast cancer patients/families (2/2105, p=1). The mutation was not found among prostate or colorectal cancer patients. CONCLUSIONS: The results of this study on familial and unselected breast, ovarian, colorectal, and prostate cancer patients suggest that RAD51D is primarily a moderate penetrance susceptibility gene for ovarian cancer, with clinical significance for the carriers.
BACKGROUND:RAD51D and RAD54L are involved in homologous recombination, and rare mutations in RAD51D were recently found in breast-ovarian cancer families. This study investigated RAD51D and RAD54L for mutations in breast and ovarian cancerpatients in the Finnish population. METHODS: The study sequenced the RAD51D and RAD54L genes in 95 breast and/or ovarian cancer families and genotyped the identified mutation in an additional 2200 breast and 553 ovarian cancerpatients and 2102 population controls. To investigate the role of the mutation in other common cancers, 1094 prostate and 980 colorectal cancerpatients were genotyped. RESULTS: In the screening of RAD51D, one deleterious founder mutation c.576+1G>A was identified in two breast-ovarian cancer families. No mutations were found in RAD54L. Altogether, the c.576+1G>A mutation was detected in 5/707 patients with a personal or family history of ovarian cancer (OR 9.16, 95% CI 1.07 to 78.56; p=0.024), with the highest frequency among breast-ovarian cancer families (3/105 vs 1/1287 controls, OR 37.82, 95% CI 3.90 to 366.91; p=0.0016), but no elevated frequency among breast cancerpatients/families (2/2105, p=1). The mutation was not found among prostate or colorectal cancerpatients. CONCLUSIONS: The results of this study on familial and unselected breast, ovarian, colorectal, and prostate cancerpatients suggest that RAD51D is primarily a moderate penetrance susceptibility gene for ovarian cancer, with clinical significance for the carriers.
Authors: Liisa M Pelttari; Tuomas Heikkinen; Deborah Thompson; Anne Kallioniemi; Johanna Schleutker; Kaija Holli; Carl Blomqvist; Kristiina Aittomäki; Ralf Bützow; Heli Nevanlinna Journal: Hum Mol Genet Date: 2011-05-25 Impact factor: 6.150
Authors: Alfons Meindl; Heide Hellebrand; Constanze Wiek; Verena Erven; Barbara Wappenschmidt; Dieter Niederacher; Marcel Freund; Peter Lichtner; Linda Hartmann; Heiner Schaal; Juliane Ramser; Ellen Honisch; Christian Kubisch; Hans E Wichmann; Karin Kast; Helmut Deissler; Christoph Engel; Bertram Müller-Myhsok; Kornelia Neveling; Marion Kiechle; Christopher G Mathew; Detlev Schindler; Rita K Schmutzler; Helmut Hanenberg Journal: Nat Genet Date: 2010-04-18 Impact factor: 38.330
Authors: Hannele Erkko; Bing Xia; Jenni Nikkilä; Johanna Schleutker; Kirsi Syrjäkoski; Arto Mannermaa; Anne Kallioniemi; Katri Pylkäs; Sanna-Maria Karppinen; Katrin Rapakko; Alexander Miron; Qing Sheng; Guilan Li; Henna Mattila; Daphne W Bell; Daniel A Haber; Mervi Grip; Mervi Reiman; Arja Jukkola-Vuorinen; Aki Mustonen; Juha Kere; Lauri A Aaltonen; Veli-Matti Kosma; Vesa Kataja; Ylermi Soini; Ronny I Drapkin; David M Livingston; Robert Winqvist Journal: Nature Date: 2007-02-07 Impact factor: 49.962
Authors: Z Kote-Jarai; D Leongamornlert; E Saunders; M Tymrakiewicz; E Castro; N Mahmud; M Guy; S Edwards; L O'Brien; E Sawyer; A Hall; R Wilkinson; T Dadaev; C Goh; D Easton; D Goldgar; R Eeles Journal: Br J Cancer Date: 2011-09-27 Impact factor: 7.640
Authors: Barbara M Norquist; Maria I Harrell; Mark F Brady; Tom Walsh; Ming K Lee; Suleyman Gulsuner; Sarah S Bernards; Silvia Casadei; Qian Yi; Robert A Burger; John K Chan; Susan A Davidson; Robert S Mannel; Paul A DiSilvestro; Heather A Lankes; Nilsa C Ramirez; Mary Claire King; Elizabeth M Swisher; Michael J Birrer Journal: JAMA Oncol Date: 2016-04 Impact factor: 31.777
Authors: Liisa M Pelttari; Laura Kinnunen; Johanna I Kiiski; Sofia Khan; Carl Blomqvist; Kristiina Aittomäki; Heli Nevanlinna Journal: Fam Cancer Date: 2016-01 Impact factor: 2.375
Authors: Douglas F Easton; Paul D P Pharoah; Antonis C Antoniou; Marc Tischkowitz; Sean V Tavtigian; Katherine L Nathanson; Peter Devilee; Alfons Meindl; Fergus J Couch; Melissa Southey; David E Goldgar; D Gareth R Evans; Georgia Chenevix-Trench; Nazneen Rahman; Mark Robson; Susan M Domchek; William D Foulkes Journal: N Engl J Med Date: 2015-05-27 Impact factor: 91.245
Authors: Lucas D Ward; Margaret M Parker; Aimee M Deaton; Ho-Chou Tu; Alexander O Flynn-Carroll; Gregory Hinkle; Paul Nioi Journal: HGG Adv Date: 2021-12-22
Authors: Marketa Janatova; Jana Soukupova; Jana Stribrna; Petra Kleiblova; Michal Vocka; Petra Boudova; Zdenek Kleibl; Petr Pohlreich Journal: PLoS One Date: 2015-06-09 Impact factor: 3.240
Authors: Ella R Thompson; Simone M Rowley; Sarah Sawyer; Diana M Eccles; Alison H Trainer; Gillian Mitchell; Paul A James; Ian G Campbell Journal: PLoS One Date: 2013-01-25 Impact factor: 3.240
Authors: Liisa M Pelttari; Johanna I Kiiski; Salla Ranta; Sara Vilske; Carl Blomqvist; Kristiina Aittomäki; Heli Nevanlinna Journal: Springerplus Date: 2015-02-24